Here are the 10-Q quarterly reports from Ensysce Bioscience WTS (ENSCW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ENSCW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENSCW filings page.
Ensysce Biosciences’ Q1 2026 results highlight rising losses and tight liquidity. Federal grant revenue was $960,999, down from $1,319,772, while operating expenses increased to $4,523,229, driven mainly by higher research and development spending. Net loss widened to $3,556,415 versus $1,945,573 a year earlier.
Cash and cash equivalents fell sharply to $745,482 from $4,310,354 at year-end, and total assets dropped to $2,167,803. Stockholders’ equity turned into a deficit of $669,012, with an accumulated deficit of $143,276,414. Management discloses substantial doubt about the company’s ability to continue as a going concern without additional capital, despite recent preferred stock and warrant financings.